ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE

August 27, 2019

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

iranian-gastro-intestinal-min
June 1, 2024

Author:

Acteropharma
International Nurse Day
May 12, 2024

Author:

Acteropharma
May 12th is celebrated as International Nurses Day, in order to appreciate nurses from all over the world. Actero Company has always appreciated the efforts of the country’s dear nurses, for this reason, on this day, express our gratitude to these honorable people.
Actero futsal match
May 8, 2024

Author:

Acteropharma
Today, the role of exercise in reducing the risk of some cancers is not hidden from anyone. Exercise has many biological effects on the body. These include: decrease in the level of sex hormones such as estrogen and growth factors that are related to the development and progression of cancer. Physical activity can be helpful in order to lose weight or maintain a healthy weight, which reduces the risk of some types of cancer. Being active is important; It keeps your body and mind healthy, prevents disease and has many benefits. According to this important matter, Actero company invited its employees to participate in sports activities for a healthy future by holding an internal futsal competition between the headquarters team and the factory team.